C-Ray Therapeutics Showcases New Clinical Insights on Alpha Therapy
During the recent Annual Congress of the European Association of Nuclear Medicine (EANM 2025) held in Barcelona, C-Ray Therapeutics (Shanghai) Co., Ltd. presented groundbreaking clinical findings related to its innovative radiopharmaceutical, 225Ac-PSMA-CY313, aimed at treating metastatic castration-resistant prostate cancer (mCRPC). This event marked a significant milestone for the company, highlighting its commitment to pioneering advancements in targeted alpha therapies.
Promising Clinical Results
The data revealed during this prestigious congress have been labeled as early evidence of the therapy's notable potential and its favorable safety profile. C-Ray's Chief Medical Officer presented two highly rated oral presentations that underscored these findings, emphasizing the significance of the data in advancing treatment options for mCRPC patients.
Feasibility Study Findings
The first presentation, titled "Feasibility study of 225Ac-PSMA-CY313 dosimetry in mCRPC patients using SPECT", detailed the company's advancements in dosimetry research pertaining to 225Ac. This study successfully established and validated a quantitative dosimetry approach through the use of SPECT/CT. This allowed for a detailed evaluation of internal radiation doses received by patients undergoing treatment. The findings indicated that tumors, particularly soft tissue lesions, received substantial absorbed doses, while critical organs, including the kidneys and liver, maintained safety within acceptable exposure thresholds. Notably, the study reported no severe adverse events (SAEs) and emphasized that the treatment opened a favorable therapeutic window for patients.
Safety and Efficacy Evaluation
The second oral presentation focused on the safety and efficacy evaluation of 225Ac-PSMA-CY313 in a cohort of 13 patients resistant to standard therapies. This presentation reported that all patients experienced reductions in prostate-specific antigen (PSA) levels, with an impressive 81.8% achieving a PSA50 response, which indicates a 50% or greater decline in PSA levels. Among those evaluated, the objective response rate (ORR) stood at 60%, showcasing promising efficacy among those heavily pretreated.
In terms of safety, most recorded adverse events were mild, with the most frequently reported side effect being xerostomia or dry mouth. This condition was observed in 11 out of 13 patients, including 10 who experienced grade 1 events and one grade 2 event, as per standard CTCAE v5.0 criteria.
A Milestone for C-Ray Therapeutics
The Chief Medical Officer of C-Ray Shanghai expressed optimism about the significance of these results being presented on an international platform. "Presenting these results on such a globally recognized stage as EANM represents a significant milestone for C-Ray," they stated. With only a handful of teams globally advancing alpha-emitting radiopharmaceuticals into clinical development, the findings attest to the robust clinical data generated by C-Ray and highlight the company's ongoing dedication to innovation.
About C-Ray Therapeutics (Shanghai) Co., Ltd.
C-Ray Therapeutics (Shanghai) is a biotechnology firm focused on the research and development of cutting-edge targeted radiopharmaceuticals. Based in Shanghai, the company is making strides in its pipeline from early research stages to clinical trials while building cutting-edge platforms for conjugation and linker technology. The firm actively pursues global partnerships aimed at enhancing innovation across various technologies.
To foster a seamless transition from early research to clinical application, C-Ray collaborates closely with its affiliate, C-Ray Therapeutics (Chengdu) Co., Ltd. This strategic relationship leverages specialized services in radiochemistry and clinical support, ensuring that the Shanghai-based company can concentrate on innovation and the expansion of its core areas of expertise.
Frequently Asked Questions
What is the main focus of C-Ray Therapeutics?
C-Ray Therapeutics specializes in developing innovative targeted radiopharmaceuticals aimed at treating complex cancers.
What clinical results were presented at EANM 2025?
They reported significant safety and efficacy findings for 225Ac-PSMA-CY313 in treating metastatic castration-resistant prostate cancer.
What was the PSA response rate observed in the study?
The study showed that 81.8% of patients achieved a PSA50 response, indicating a substantial decline in PSA levels.
What safety profile was reported for 225Ac-PSMA-CY313?
The therapy demonstrated a favorable safety profile, with most adverse events classified as mild.
How does C-Ray Therapeutics ensure smooth developmental transitions?
The company collaborates with C-Ray Therapeutics (Chengdu) to integrate early research with clinical application effectively.
